The iQ Group Global, an Australian consortium of life science and financial services companies, developed a biosensor capable of accurately measuring glucose in a person’s saliva.
This groundbreaking technology is the world’s first non-invasive, saliva-based glucose test for diabetes management that measures glucose in saliva rather than blood. The saliva-based glucose test is being developed to improve the quality of life for over 425 million people living with diabetes globally.
The technology, invented by Professor Paul Dastoor and his team at the Centre of Organic Electronics at the University of Newcastle in Australia, comprises the Glucose Biosensor Unit and a digital healthcare app. The iQ Group Global acquired the biosensor technology in 2016 and has accelerated its development for diagnostic applications. The Glucose Biosensor Unit is a small, disposable strip, which when exposed to an individual’s saliva instantly provides a glucose measurement. The glucose measurement will be presented in real-time, via a proprietary digital app on a patient’s smart device, said a press release.
“Diabetes is a global epidemic, with 1 in 11 adults living with the disease. Achieving normoglycemia is one of the main targets for diabetes patients. However, finger prick testing is a painful and frustrating process, with many citing the pain as the main reason for poor adherence to testing protocols. By eradicating the need for finger prick blood tests, the saliva-based test will lead to increased glucose monitoring and better healthcare outcomes among these patients,” says Dr. George Syrmalis, Chief Executive Officer and Chairman of The iQ Group Global.
The Glucose Biosensor Unit
The patent protected modified organic thin film transistors work in combination with Glucose Oxidase (GOX) to initiate an electrochemical reaction that produces an electrical signal. This signal can be displayed on the patient’s smart device in real time. Due to its high sensitivity the biosensor can detect glucose levels at considerably lower levels than in blood. It has a linear glucose sensing capability at concentrations of 100 times lower than current blood measuring methodologies.
Future Medical Applications
The iQ Group Global is currently working on a pilot research and development program with the University of Newcastle to expand beyond the saliva glucose diagnostic test and develop the platform of Point of Care Diagnostic Tests beginning with tumor markers, hormones, and communicable diseases.